People · Operator
Named in public records as an officer, director or promoter · active 2010–2022 · Biotech / Pharma, Healthtech, Biotechnology, Other Health Care, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Appello Pharmaceuticals, Inc. | — | Biotech / Pharma | Series B | $29.0M | $263.7M | 2018 |
| AngelEye Health, Inc. | — | Healthtech | Series A | $16.1M | $11.4M | 2022 |
| Cerebrotech Medical Systems, Inc. | — | Biotechnology | Seed | $9.0M | $137.3M | 2012 |
| GenomOncology, LLC | — | Other Health Care | Seed | $5.8M | $79.3M | 2019 |
| Device Innovation Group, LLC | — | Other Health Care | Seed | $4.0M | $99.1M | 2011 |
| VenX, LLC | — | Other Health Care | Seed | $3.7M | $10.3M | 2010 |
| Goba, Llc | — | Other Technology | Pre-Seed | $1.3M | $26.6M | 2010 |
Brian Laden at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Brian Laden on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Navroze Mehta | 2 | 8 |
| Christopher Rand | 2 | 3 |
| Stuart Young | 1 | 75 |
| John Harris | 1 | 20 |
| JEFF SMITH | 1 | 17 |
| Andrew Firlik | 1 | 14 |
| Byron Smith | 1 | 8 |
| Hans Hickler | 1 | 5 |
| Joseph C. Cook, III | 1 | 4 |
| Joseph Cook III | 1 | 4 |
| Jerry Gibson | 1 | 3 |
| Len Pagon | 1 | 3 |
| Lee Zapis | 1 | 3 |
| Mitchell Levinson | 1 | 2 |
| Joe Cook, Jr. | 1 | 2 |
| Jeff Landman | 1 | 2 |
| Christopher P. Rand | 1 | 2 |
| Manuel J. Glynias | 1 | 1 |
| Martin C. Dieck | 1 | 1 |
| Brad J. Wertz | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.